Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study

This publication has 16 references indexed in Scilit:

• Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer
  Cancer Chemotherapy and Pharmacology, 2002
• Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor
  Anti-Cancer Drugs, 2002
• Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
  Journal of Clinical Oncology, 2001
• The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?
  European Journal Of Cancer, 2000
• Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors
  Journal of Clinical Oncology, 1999
• Phase II of doxorubicin/taxol in metastatic breast cancer
  Breast Cancer Research and Treatment, 1999
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
  Journal of Clinical Oncology, 1998
• Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
  Journal of Clinical Oncology, 1997
• A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC
  British Journal of Cancer, 1996
• Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
  European Journal Of Cancer, 1994